EW
ALLO icon

Evoke Wealth’s Allogene Therapeutics ALLO Stock Holding History

Evoke Wealth’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-32
Closed – – 384
2022
Q3 		$0 Hold
32
– – ﹤0.01% 1164
2022
Q2 		$0 Hold
32
– – ﹤0.01% 1163
2022
Q1 		$0 Hold
32
– – ﹤0.01% 1154
2021
Q4 		$0 Hold
32
– – ﹤0.01% 1172
2021
Q3 		$0 Hold
32
– – ﹤0.01% 1136
2021
Q2 		$1K Hold
32
– – ﹤0.01% 1095
2021
Q1 		$1K Hold
32
– – ﹤0.01% 1085
2020
Q4 		$1K Hold
32
– – ﹤0.01% 936
2020
Q3 		$1K Buy
+32
New +$1.21K ﹤0.01% 901

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Evoke Wealth's ALLO Position: Q4 2022 in Review

Evoke Wealth sold out of Allogene Therapeutics (ALLO) in Q4 2022, closing a stake of 32 shares.

Evoke Wealth first reported a position in ALLO in Q3 2020 and held it in 9 quarters. The position peaked at $1K in Q2 2021. 168 funds tracked by Wall St. Rank hold ALLO as of Q4 2022.

  • Evoke Wealth reported no remaining Allogene Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Evoke Wealth sold 32 Allogene Therapeutics shares in Q4 2022.
  • Evoke Wealth first reported a position in Allogene Therapeutics in Q3 2020 and held it in 9 quarters.
  • Evoke Wealth's Allogene Therapeutics position peaked at $1K in Q2 2021.
  • 168 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2022.

Based on Evoke Wealth's 13F filing for Q4 2022, filed 10 Feb 2023.